Barclays
ANIK icon

Barclays’s Anika Therapeutics ANIK Stock Holding History

Barclays’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-120,000
Closed -$2.76M – 7512
2013
Q3 		$2.76M Buy
+120,000
New +$2.69M ﹤0.01% 2226

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Barclays's ANIK Position: Q2 2026 in Review

Barclays reduced its Anika Therapeutics (ANIK) stake by 1.2% in Q2 2026, selling an estimated $9.03K and leaving 52,319 shares worth $765K. The position accounts for ﹤0.01% of the portfolio, ranked #2953.

Barclays first reported a position in ANIK in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.93M in Q3 2019. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Barclays held 52,319 shares of Anika Therapeutics worth $765K as of Q2 2026.
  • Barclays sold 609 Anika Therapeutics shares in Q2 2026, an estimated $9.03K.
  • Anika Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2953 holding.
  • Barclays first reported a position in Anika Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Anika Therapeutics position peaked at $1.93M in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.